| pubmed-article:18404268 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18404268 | lifeskim:mentions | umls-concept:C0376358 | lld:lifeskim |
| pubmed-article:18404268 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
| pubmed-article:18404268 | lifeskim:mentions | umls-concept:C0203608 | lld:lifeskim |
| pubmed-article:18404268 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:18404268 | pubmed:dateCreated | 2008-6-13 | lld:pubmed |
| pubmed-article:18404268 | pubmed:abstractText | We reported recently the induction of selective iodide uptake in prostate cancer cells (LNCaP) by prostate-specific antigen (PSA) promoter-directed sodium iodide symporter (NIS) expression that allowed a significant therapeutic effect of (131)I. In the current study, we studied the potential of the high-energy alpha-emitter (211)At, also transported by NIS, as an alternative radionuclide after NIS gene transfer in tumors with limited therapeutic efficacy of (131)I due to rapid iodide efflux. | lld:pubmed |
| pubmed-article:18404268 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18404268 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18404268 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18404268 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18404268 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18404268 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18404268 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18404268 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18404268 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18404268 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18404268 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:18404268 | pubmed:issn | 1619-7070 | lld:pubmed |
| pubmed-article:18404268 | pubmed:author | pubmed-author:MorrisJohn... | lld:pubmed |
| pubmed-article:18404268 | pubmed:author | pubmed-author:WolfIngoI | lld:pubmed |
| pubmed-article:18404268 | pubmed:author | pubmed-author:KnappWolfram... | lld:pubmed |
| pubmed-article:18404268 | pubmed:author | pubmed-author:GökeBurkhardB | lld:pubmed |
| pubmed-article:18404268 | pubmed:author | pubmed-author:Senekowitsch-... | lld:pubmed |
| pubmed-article:18404268 | pubmed:author | pubmed-author:SpitzwegChris... | lld:pubmed |
| pubmed-article:18404268 | pubmed:author | pubmed-author:MeyerGeerd... | lld:pubmed |
| pubmed-article:18404268 | pubmed:author | pubmed-author:StarkHans-Jür... | lld:pubmed |
| pubmed-article:18404268 | pubmed:author | pubmed-author:WillhauckMich... | lld:pubmed |
| pubmed-article:18404268 | pubmed:author | pubmed-author:SamaniBibi-Ra... | lld:pubmed |
| pubmed-article:18404268 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18404268 | pubmed:volume | 35 | lld:pubmed |
| pubmed-article:18404268 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18404268 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18404268 | pubmed:pagination | 1272-81 | lld:pubmed |
| pubmed-article:18404268 | pubmed:meshHeading | pubmed-meshheading:18404268... | lld:pubmed |
| pubmed-article:18404268 | pubmed:meshHeading | pubmed-meshheading:18404268... | lld:pubmed |
| pubmed-article:18404268 | pubmed:meshHeading | pubmed-meshheading:18404268... | lld:pubmed |
| pubmed-article:18404268 | pubmed:meshHeading | pubmed-meshheading:18404268... | lld:pubmed |
| pubmed-article:18404268 | pubmed:meshHeading | pubmed-meshheading:18404268... | lld:pubmed |
| pubmed-article:18404268 | pubmed:meshHeading | pubmed-meshheading:18404268... | lld:pubmed |
| pubmed-article:18404268 | pubmed:meshHeading | pubmed-meshheading:18404268... | lld:pubmed |
| pubmed-article:18404268 | pubmed:meshHeading | pubmed-meshheading:18404268... | lld:pubmed |
| pubmed-article:18404268 | pubmed:meshHeading | pubmed-meshheading:18404268... | lld:pubmed |
| pubmed-article:18404268 | pubmed:meshHeading | pubmed-meshheading:18404268... | lld:pubmed |
| pubmed-article:18404268 | pubmed:meshHeading | pubmed-meshheading:18404268... | lld:pubmed |
| pubmed-article:18404268 | pubmed:meshHeading | pubmed-meshheading:18404268... | lld:pubmed |
| pubmed-article:18404268 | pubmed:meshHeading | pubmed-meshheading:18404268... | lld:pubmed |
| pubmed-article:18404268 | pubmed:meshHeading | pubmed-meshheading:18404268... | lld:pubmed |
| pubmed-article:18404268 | pubmed:meshHeading | pubmed-meshheading:18404268... | lld:pubmed |
| pubmed-article:18404268 | pubmed:meshHeading | pubmed-meshheading:18404268... | lld:pubmed |
| pubmed-article:18404268 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18404268 | pubmed:articleTitle | The potential of 211Astatine for NIS-mediated radionuclide therapy in prostate cancer. | lld:pubmed |
| pubmed-article:18404268 | pubmed:affiliation | Department of Internal Medicine II, Ludwig-Maximilians-University, Munich, Germany. | lld:pubmed |
| pubmed-article:18404268 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18404268 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:18404268 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18404268 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18404268 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18404268 | lld:pubmed |
